Corcept Therapeutics Inc Ovarian Cancer Program Update Transcript
Good morning. Welcome to Corcept's Ovarian Cancer Program Update. I'm Atabak Mokari, Corcept's Chief Financial Officer. I want to begin by thanking those of you joining us virtually as well as a big thank you to those of you joining us here in New York. We are delighted to host this event to highlight one of our important clinical development programs.
Statements during this meeting, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to differ materially from those such statements expressed or implied. These forward-looking statements are described in our press release that was issued yesterday, and the risk and uncertainties that may affect them are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q. Please refer to those documents for additional information regarding these forward-looking statements and the factors that may affect them. We disclaim any intention or duty to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |